Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gain Therapeutics, Inc. - Common Stock (NQ:GANX)

1.805 +0.075 (+4.34%)
Streaming Delayed Price Updated: 2:14 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gain Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
GANX Stock Earnings: Gain Therapeutics Misses EPS for Q2 2024 ↗
GANX stock results show that Gain Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
7 Sorry Biotech Stocks Set to Make Investors Sad ↗
Biotech stocks can be extremely challenging because it takes a long time to bring a therapy to market. Here are some biotech stocks to sell. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
Pre-market stock movers are a hot topic on Friday and we're breaking down all of the latest news sending shares higher and lower! 
Via InvestorPlace
News headline image
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
Data demonstrates improvement in cognitive function in GBA1 Parkinson’s disease model in addition to reversal of motor function deficits 
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
From Gain Therapeutics, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Gain Therapeutics Inc. (NASDAQ: GANX) Releases Pricing of Underwritten Public Offering, Projected to Reach $11M
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
S&P 500 Edges Lower; RH Shares Plunge After Q1 Results ↗
 
Via Benzinga
Topics Stocks
News headline image
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Gold Gains 1%; US Consumer Sentiment Falls In June ↗
 
Via Benzinga
News headline image
Dear ARM Stock Fans, Mark Your Calendars for June 24 ↗
Arm stock is up on Friday and is preparing for a catalyst later this month when it replaces Sirius XM on the Nasdaq 100. 
Via InvestorPlace
News headline image
Dow Tumbles Over 200 Points; Adobe Earnings Top Views ↗
 
Via Benzinga
Topics Stocks
News headline image
Why Is Gain Therapeutics (GANX) Stock Down 25% Today? ↗
Gain Therapeutics stock is down on Friday after the company priced an $11 million public offering for roughly 7 million shares of GANX. 
Via InvestorPlace
News headline image
Why Adobe Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
Pre-market stock movers are worth checking out on Friday as we dive into all of the biggest news moving shares this morning! 
Via InvestorPlace
News headline image
Gain Therapeutics Announces Pricing of $11.0 Million Public Offering
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Announces Proposed Public Offering
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024
New data demonstrating improvement of cognitive performance after treatment with GT-02287 in preclinical model of GBA1 Parkinson’s disease 
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
GANX Stock Earnings: Gain Therapeutics Beats EPS for Q1 2024 ↗
GANX stock results show that Gain Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
From Gain Therapeutics, Inc.
Via GlobeNewswire
News headline image
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
From Gain Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.